Intellectual property lawyer focusing on patent litigation.
Has represented some of the largest pharmaceutical companies in the world in litigation of some of their blockbuster biological molecules.

Dr. Jason Weil’s practice encompasses a range of technologies, including:

Monoclonal antibody therapies
Biosimilars
DNA diagnostics
Medical devices.

Jason was part of the team that represented pharmaceutical companies and an inventor in patent infringement actions in the District of Delaware. The accused products in those cases were recently approved monoclonal antibody drugs that manipulated the body’s immune system to treat cancer.

He successfully represented Cornell University before the Patent Trial and Appeal Board (PTAB), leading to denial of institution of three petitions for inter partes review challenging Cornell patents related to Cornell’s DNA detection technology. He also represented another large corporation before the PTAB, leading to denial of institution of a petition for inter partes review relating to certain dental materials.

In addition to his patent litigation work, Jason has successfully advocated for pro bono clients on a variety of matters. He recently served on the trial team in a large pro bono case involving the former President of Bolivia, examining and cross-examining witnesses during a three-week federal jury trial. The case centered on a claim under the Torture Victim Protection Act that was brought by several Bolivian citizens against the former President and the former Minister of Defense of Bolivia.

He has represented abused and neglected children before the Family Court in Philadelphia as a volunteer attorney with the Support Center for Child Advocates. He also worked as a volunteer attorney with the Pennsylvania Immigration Resource Center to successfully represent a Somali man seeking asylum before the immigration court.

Earlier in his career, Jason served as a law clerk to The Honorable Richard Linn of the U.S. Court of Appeals for the Federal Circuit. While in law school, he served as an intern/analyst at the National Commission on the BP Deepwater Horizon Oil Spill and Offshore Drilling and as a judicial intern to The Honorable T.S. Ellis III of the United States District Court for the Eastern District of Virginia.

Prior to attending law school, Jason earned his Ph.D. in biology from the Johns Hopkins University and his B.S. in biotechnology from the Rochester Institute of Technology. His graduate work focused on understanding the cellular mechanism of nonsense-mediated mRNA decay.

Representative Work

Represented one of the largest multinational pharmaceutical companies in a patent infringement case where a major competitor of the client launched a competing cancer drug. Achieved a very favorable monetary settlement for our client.
Counseled an innovator pharmaceutical company and a university in one of the first biosimilar patent challenges. Leveraged deep understanding of biological molecules and filed a successful motion to dismiss a potential competitor’s claim. Subsequently, the client brought suit under the Biologics Price Competition and Innovation Act.
Represented a large multinational corporation in inter partes review proceedings related to dental materials.
Advised pharmaceutical companies in a correction of inventorship action.
Counseled a university and a life science research products manufacturer in inter partes review proceedings related to DNA sequencing technology.

Education
J.D., The George Washington University Law School, with highest honors, 2011
Ph.D., Johns Hopkins University, 2008
B.S., Rochester Institute of Technology, with highest honors, 2001

Clerkships
U.S.C.A., Federal Circuit

Bar Admissions
Pennsylvania
U.S. Patent and Trademark Office

Recognitions

The Legal Intelligencer, Lawyer on the Fast Track, 2019.

Speeches and Publications

“Tips to Mitigate the Effect of IPRs,” New Jersey Intellectual Property Law Association, January 23, 2020.
“Patentable Subject Matter—Proposed Legislative Changes,” Presentations to AdvaMed—Advanced Medical Technology Association, September 18 & 19, 2019.
“Patent Dispute Resolution Provisions of the BPCIA in Light of Amgen v. Sandoz Case Explored!” The Knowledge Group, April 22, 2016.
“3rd Annual Naples Patent Law Experts Conference,” Faculty Member, February 9 and 10, 2015.
“Hot Topics in Patent Law,” Delaware Valley Chapter of the Association of Corporate Counsel, July 8, 2014.